These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 1175123

  • 21. Tumor growth patterns in multiple myeloma.
    Hokanson JA, Brown BW, Thompson JR, Drewinko B, Alexanian R.
    Cancer; 1977 Mar; 39(3):1077-84. PubMed ID: 912647
    [Abstract] [Full Text] [Related]

  • 22. Sequential therapy compared with combination therapy in multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):163-71. PubMed ID: 1111465
    [Abstract] [Full Text] [Related]

  • 23. Multiple myeloma without detectable Ig synthesis.
    Ferraris AM, Haupt E, Ratti M.
    Acta Haematol; 1979 Jan; 62(5-6):257-61. PubMed ID: 121666
    [Abstract] [Full Text] [Related]

  • 24. Multiple myeloma. II. The value of melphalan.
    Bernard DB, Lynch SR, Bothwell TH, Bezwoda WR, Stevens K, Shulman G.
    S Afr Med J; 1974 May 18; 48(24):1026-8. PubMed ID: 4835772
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D, Bosković D, Radosević N, Elezović I, Tomin D, Gotić M, Antunović P.
    Srp Arh Celok Lek; 1996 May 18; 124(11-12):292-6. PubMed ID: 9132962
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myeloma.
    Presant CA, Klahr C.
    Cancer; 1978 Sep 18; 42(3):1222-7. PubMed ID: 698913
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Prognostic factors for multiple myeloma in the dog.
    Matus RE, Leifer CE, MacEwen EG, Hurvitz AI.
    J Am Vet Med Assoc; 1986 Jun 01; 188(11):1288-92. PubMed ID: 3721983
    [Abstract] [Full Text] [Related]

  • 37. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
    Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C, Lamy T, Grosbois B, Dauriac C, Dorvaux V, Bay JO, Monconduit M, Harousseau JL, Duguet C, Duhamel A, Facon T.
    Hematol J; 2002 Jun 01; 3(4):185-92. PubMed ID: 12189564
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone.
    Baldini L, Radaelli F, Chiorboli O, Fumagalli S, Cro L, Segala M, Cesana BM, Polli EE, Maiolo AT.
    Cancer; 1991 Jul 01; 68(1):62-7. PubMed ID: 2049754
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.